CyFlow CD266 Purified
品番 | AZ756227 | ||
---|---|---|---|
抗体名 | Anti-H/M CD266 PURI,ITEM-4 | ||
包装単位 | 0.1 mg | ||
濃度 | 1 mg/ml | ||
容量 | 0.1 ml | ||
関連製品 (アイソタイプコントロール) |
Mouse IgG2b Purified (AS131472) Mouse IgG2b Purified (CK823368) |
||
反応性|交差吸着 | Human | Mouse | レーザー | |
抗原 | CD266, TWEAK-R, TNFRSF12A | 最大蛍光波長 | - |
クローン | ITEM-4 | 最大励起波長 | - |
ホスト | Mouse | 標識/Format | Purified |
アイソタイプ | IgG2b | 研究分野 | Immunophenotyping | Apoptosis |
クローナリティ | monoclonal | 用途 | Flow cytometry |
Anti-H/M CD266 PURI,ITEM-4
特異性
The mouse monoclonal antibody ITEM-4 recognizes CD266 (TWEAK R) antigen, a TNFR superfamily receptor for CD255 (TWEAK), a TNF-like weak inducer of apoptosis.
抗原情報
CD266 (TWEAK R, TNFRSF12A), also known as FN14 (fibroblast growth factor-inducible 14), is a receptor for CD255 (TWEAK), the TNF-like weak inducer of apoptosis. CD266 is expressed on endothelial cells, as well as on some cancer tissues, and plays a role in CD255-induced endothelial cell migration, proliferation, and angiogenesis. The CD255-CD266 interaction, or antibody-mediated triggering of CD266 is also able to induce apoptosis and necrosis in CD266-positive cells (including tumor cells), which might have therapeutic potential.
利用方法
保存方法
Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
安定性情報
Do not use after expiration date stamped on vial label.
レファレンス
• Nakayama M, Ishidoh K, Kojima Y, Harada N, Kominami E, Okumura K, Yagita H: Fibroblast growth factor‑inducible 14 mediates multiple pathways of TWEAK‑induced cell death. J·Immunol. 2003·Jan·1; 170(1):341‑8. <·PMID:·12496418·>
• Roos C, Wicovsky A, Müller N, Salzmann S, Rosenthal T, Kalthoff H, Trauzold A, Seher A, Henkler F, Kneitz C, Wajant H: Soluble and transmembrane TNF‑like weak inducer of apoptosis differentially activate the classical and noncanonical NF‑kappa B pathway. J·Immunol. 2010·Aug·1; 185(3):1593‑605. <·PMID:·20610643·>
• Sanz AB, Sanchez-Niño MD, Carrasco S, Manzarbeitia F, Ruiz-Andres O, Selgas R, Ruiz-Ortega M, Gonzalez-Enguita C, Egido J, Ortiz A: Inflammatory cytokines and survival factors from serum modulate tweak‑induced apoptosis in PC‑3 prostate cancer cells. PLoS·One. 2012; 7(10):e47440. <·PMID:·23077618·>
• Yoriki R, Akashi S, Sho M, Nomi T, Yamato I, Hotta K, Takayama T, Matsumoto S, Wakatsuki K, Migita K, Yagita H, Nakajima Y: Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer. Exp·Ther·Med. 2011·Jan; 2(1):103‑108. <·PMID:·22977477·>
Available Safety Data Sheets
CyFlow™ monoclonal antibodies SDS CA EN